Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting now · Phase 3

Conditions studied: Advanced or Metastatic Non-small Cell Lung Cancer

In brief

This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.

Key facts

Study ID: NCT07170995
Run by: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
People needed: 460
Starts: 2025-10-22
Expected to finish: 2030-12-01
Last updated by the study team: 2025-11-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Voluntary participation and written informed consent.
18-75 years old, no gender limitation.
Newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation.
Confirmed tumor PD-L1 status prior to randomization.
Eastern Cooperative Oncology Group (ECOG) score: 0-1
With a life expectancy ≥ 3 months.
At least one measurable lesion according to RECIST v1.1.

You may not qualify if…

Have untreated central nervous system metastasis; or have meningeal metastasis or spinal cord compression;
Uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites;
Previous or co-existing malignancies；
Have Active or prior documented autoimmune or inflammatory disorders;
Active hepatitis B or hepatitis C, or with a history of immunodeficiency;
Have an active or past medical history of interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis.

Where it is running

Affiliated Cancer Hospital of Shandong First Medical University — Jinan, Shandong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.